Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Unresectable, locally advanced measurable (at least bidirectional) adenocarcinoma of the pancreas (regardless of site) proven by biopsy or cytology and confirmed by surgical consultation~* Informed consent and authorization for the release of health information signed by the patient~* Karnofsky performance status \>= 70%~* Life expectancy \>= 3 months~* Females of childbearing potential and males must use an effective method of contraception~Exclusion Criteria:~* Metastatic (stage IV) disease (including involvement of the colon, adrenals, or kidney, or radiographic evidence of peritoneal seeding or pulmonary metastases)~* Previous chemotherapy, radiotherapy of other treatment for PC~* Gastric or duodenal wall invasion by the primary PC as assessed by CT or MRI and EUS staging~* Gastric or duodenal ulcer (at least 10 mm in size) within 10 mm of expected endoscopy puncture site(s) for PDT~* Esophageal or gastric varices~* Cystic component \>= 25% the total volume of the tumor~* Ascites detected by CT, ultrasound (US) or MRI; (trace ascites will not be an exclusion)~* Bulky celiac adenopathy (i.e., \>= 2.5 cm in diameter)~* Diagnosis of islet cell tumor, lymphoma, metastatic lesion, acinar cell (or other atypical pathologic malignancy)~* History of other malignancy in the past 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer or localized/early stage prostate cancer~* Unable to receive or previously intolerant of moderate and/or deep sedation~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \>= 3 x upper limit of normal (ULN)~* Total bilirubin \>= 3 x ULN~* Alkaline phosphatase \>= 3 x ULN~* International normalized ratio (INR) \>= 1.5~* Partial thromboplastin time (PTT) ratio \>= 1.5~* Serum creatinine \>= 2.0 mg/dL~* Hematocrit =\< 28% or hemoglobin =\< 9 g/dL, but may have red blood cell (RBC) transfusion~* Platelet count =\< 100,000/microliter (uL)~* Absolute neutrophil count (ANC) =\< 1500/uL~* Clinically significant pancreatitis within 12 weeks of treatment with protocol therapy~* Contraindication to EUS-guided needle puncture into the pancreas~* History of coagulopathy or known thrombophilias~* Use of anticoagulants that cannot be discontinued both 5 days before and 5 days after EUS~* Clinical evidence of active infection of any type, including hepatitis B or C virus~* Pregnant or lactating women~* Experimental medications within the last 4 weeks prior to day 1~* Any surgery (including diagnostic laparoscopy and/or biliary +/- duodenal palliative bypass for inoperable PC) within the 2 weeks prior to day 1 of study protocol~* Chronic systemic corticosteroid use at superphysiologic doses (\>= 10 mg prednisone per day or equivalent)~* Inability to avoid exposure of skin or eyes to direct sunlight or bright indoor light for at least 30 days~* Porphyria~* Inability to obtain venous access in the antecubital region to administer PHO or sedation for endoscopy procedures~* Significant concurrent medical or psychiatric illness which, in the opinion of the principal investigator would interfere with trial participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- porfimer sodium, EUS-PDT, gemcitabine (Type: EXPERIMENTAL): Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).